rss
J Clin Pathol 63:777-781 doi:10.1136/jcp.2010.077768
  • Original article

Lymphoma occurring in patients with cutaneous melanoma

  1. Richard A Scolyer2,3,4
  1. 1Erasmus MC, Rotterdam, The Netherlands
  2. 2Melanoma Institute Australia, Sydney, New South Wales, Australia
  3. 3Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
  4. 4Department of Pathology, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
  5. 5Department of Pathology, University of Western Sydney, Sydney, New South Wales, Australia
  6. 6Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia
  1. Correspondence to Rajmohan Murali, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; rajmohan.murali{at}sswahs.nsw.gov.au
  • Accepted 8 June 2010
  • Published Online First 29 July 2010

Abstract

Background Non-melanoma malignancies are not uncommon in patients with melanoma. This study sought to determine the incidence of lymphoma in patients with melanoma compared with the general population, and to characterise their clinical and pathological features.

Methods Patients diagnosed with melanoma and lymphoma between January 1992 and December 2007 were identified from the databases of Melanoma Institute Australia (MIA) and the Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital (RPAH). The clinical histories of the patients in the MIA database and pathology reports in the RPAH archives were reviewed. The incidence risk for melanoma and non-Hodgkin lymphoma was obtained from Australian Cancer Incidence and Mortality registry data.

Results Of 18 226 patients with melanoma, 55 (0.3%) had lymphoma. Lymphoma was diagnosed subsequent to melanoma in 23 (41.8%) patients, prior to melanoma in 7 (12.7%) patients, and concurrently with melanoma in 25 (45.5%) patients. 53 (96.4%) patients developed non-Hodgkin lymphoma (NHL), the most common subtypes being chronic lymphocytic leukaemia/small lymphocytic lymphoma (49.1%), follicular lymphoma (23.6%) and diffuse large B-cell lymphoma (16.4%). Two (3.6%) patients developed Hodgkin lymphoma. Melanoma patients had a significantly higher risk of developing NHL than the general population (standardised incidence rate 3.5).

Conclusions A small but significant proportion of patients with melanoma develop lymphoma, either synchronously or metachronously. Lymph node specimens from melanoma patients might harbour lymphoma, and might represent the first recognised site of disease. A high index of suspicion for lymphoma when evaluating lymph nodes from patients with melanoma will ensure prompt diagnosis and appropriate management.

Footnotes

  • Funding Cancer Institute New South Wales.

  • Competing interests None to declare.

  • Ethics approval This study was conducted with the approval of the Sydney South West Area Health Service Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.